{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T01:06:30Z","timestamp":1770339990381,"version":"3.49.0"},"reference-count":59,"publisher":"Touch Medical Media, Ltd.","issue":"1","license":[{"start":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T00:00:00Z","timestamp":1518739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"This article is published under the Creative Commons Attribution Non-commercial License."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<p>There is an increasing prevalence of obesity worldwide, associated with significant morbidity and mortality, which frequently reduces quality of life and life expectancy. Consequently, there is a substantial and growing personal and economic burden necessitating the development of more effective therapies for obesity. Glucagon-like peptide-1 receptor analogues (GLP-1RAs) are licensed for the treatment of type 2 diabetes (T2D), and there is substantial evidence that these drugs not only improve cardiovascular outcomes but also promote weight loss. More recent evidence supports the use of the GLP-1RAs liraglutide and semaglutide in people with obesity without T2D. This article discusses the results of the major cardiovascular outcome trials for GLP-1RAs in people with T2D, the SCALE Obesity and Prediabetes study (Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with co-morbidities: SCALE\u2122 - Obesity and Pre-diabetes; ClinicalTrials.gov identifier: NCT01272219; investigating liraglutide) and the STEP studies (Semaglutide treatment effect in people with obesity; assorted studies; investigating subcutaneous semaglutide). We also highlight the importance of a cost-effective approach to obesity pharmacotherapy. Clinicians should consider the use of GLP-1RAs in people with obesity, especially those with T2D or other obesity-related diseases, such as hypertension and dyslipidaemia. Ongoing trials, as well as clinical and cost-effectiveness appraisals, are anticipated over the next 12 months, and their findings may change the current landscape of obesity pharmacotherapy.<\/p>","DOI":"10.17925\/ee.2022.18.1.43","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T12:50:03Z","timestamp":1657975803000},"page":"43","source":"Crossref","is-referenced-by-count":9,"title":["Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity"],"prefix":"10.17925","volume":"18","author":[{"given":"David M","family":"Williams","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Staff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C","family":"Bain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thinzar","family":"Min","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Diabetes and Endocrinology, Singleton Hospital, Swansea Bay University Health Board, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Diabetes Research Group, Swansea University Medical School, Swansea University, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Diabetes and Endocrinology, Neath Port Talbot Hospital, Swansea Bay University Health Board, Swansea, UK","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7274","reference":[{"key":"ref1","unstructured":"UK Parliament. House of Commons Library: Obesity Statistics. 2019. Available at: https:\/\/researchbriefings.parliament.uk\/ResearchBriefing\/Summary\/SN03336 (accessed 8 April 2021)."},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bluher M. Obesity: Global epidemiology and pathogenesis.\n                      Nat Rev Endocrinol\n                      . 2019;15:288\u201398.","DOI":"10.1038\/s41574-019-0176-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: Shaped by global drivers and local environments.\n                      Lancet\n                      . 2011;378:804\u201314.","DOI":"10.1016\/S0140-6736(11)60813-1"},{"key":"ref4","unstructured":"Centers for Disease Control and Prevention. Adult Obesity Facts. Available at: cdc.gov\/obesity\/data\/adult.html (accessed 5 October 2021)."},{"key":"ref5","unstructured":"World Health Organization. Obesity and Overweight. Available at: who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (accessed 8 May 2021)."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Dinsa GD, Goryakin Y, Fumagalli E, Suhrcke M. Obesity and socioeconomic status in developing countries: A systematic review.\n                      Obes Rev\n                      . 2012;13:1067\u201379.","DOI":"10.1111\/j.1467-789X.2012.01017.x"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults.\n                      N Engl J Med\n                      . 2010;363:2211\u20139.","DOI":"10.1056\/NEJMoa1000367"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years.\n                      N Engl J Med\n                      . 2017;377:13\u201327.","DOI":"10.1056\/NEJMoa1614362"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Sanchis-Gomar F, Lavie CJ, Mehra MR, et al. Obesity and outcomes in COVID-19: When an epidemic and pandemic collide.\n                      Mayo Clin Proc\n                      . 2020;95:1445\u201353.","DOI":"10.1016\/j.mayocp.2020.05.006"},{"key":"ref10","unstructured":"Public Health England. Health Matters: Obesity and the Food Environment. Available at: gov.uk\/government\/publications\/health-matters-obesity-and-the-food-environment (accessed 8 April 2021)."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Look ARG, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: Four-year results of the Look AHEAD trial.\n                      Arch Intern Med\n                      . 2010;170:1566\u201375.","DOI":"10.1001\/archinternmed.2010.334"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Cheng J, Gao J, Shuai X, et al. The comprehensive summary of surgical versus non-surgical treatment for obesity: A systematic review and meta-analysis of randomized controlled trials.\n                      Oncotarget\n                      . 2016;7:39216\u201330.","DOI":"10.18632\/oncotarget.9581"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults.\n                      Obes Facts\n                      . 2015;8:402\u201324.","DOI":"10.1159\/000442721"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: An Endocrine Society clinical practice guideline.\n                      J Clin Endocrinol Metab\n                      . 2015;100:342\u201362.","DOI":"10.1210\/jc.2014-3415"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.\n                      Health Technol Assess\n                      . 2001;5:1\u201381.","DOI":"10.3310\/hta5180"},{"key":"ref16","unstructured":"Sherman MM, Ungureanu S, Rey JA. Naltrexone\/bupropion ER (Contrave): Newly approved treatment option for chronic weight management in obese adults.\n                      P T\n                      . 2016;41:164\u201372."},{"key":"ref17","unstructured":"National Institute for Health and Care Excellence. Naltrexone-Bupropion for Managing Overweight and Obesity. Available at: nice.org.uk\/guidance\/ta494\/resources\/naltrexonebupropion-for-managing- overweight-and-obesity-pdf-82605086955205 (accessed 8 April 2021)."},{"key":"ref18","unstructured":"National Institute for Health and Care Excellence. Liraglutide for managing overweight and obesity. Available at: nice.org.uk\/guidance\/ta664\/chapter\/1-Recommendations (accessed 8 April 2021)."},{"key":"ref19","unstructured":"Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. 2021. Available at: fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014 (accessed 8 April 2021)."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Yin WL, Bain SC, Min T. The effect of glucagon-like peptide-1 receptor agonists on renal outcomes in type 2 diabetes.\n                      Diabetes Ther\n                      . 2020;11:835\u201344.","DOI":"10.1007\/s13300-020-00798-x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials.\n                      Lancet Diabetes Endocrinol\n                      . 2019;7:776\u201385.","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.\n                      J Clin Endocrinol Metab\n                      . 1986;63:492\u20138.","DOI":"10.1210\/jcem-63-2-492"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Nauck M, St\u00f6ckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.\n                      Diabetologia\n                      . 1986;29:46\u201352.","DOI":"10.1007\/BF02427280"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.\n                      Proc Natl Acad Sci U S A\n                      . 1987;84:3434\u20138.","DOI":"10.1073\/pnas.84.10.3434"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gilbert MP, Pratley RE. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: Review of head-to-head clinical trials.\n                      Front Endocrinol (Lausanne)\n                      . 2020;11:178.","DOI":"10.3389\/fendo.2020.00178"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Min T, Bain SC. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials.\n                      Diabetes Ther\n                      . 2021;12:143\u201357.","DOI":"10.1007\/s13300-020-00981-0"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1.\n                      Cell Metab\n                      . 2018;27:740\u201356.","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Nogueiras R, P\u00e9rez-Tilve D, Veyrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity.\n                      J Neurosci\n                      . 2009;29:5916\u201325.","DOI":"10.1523\/JNEUROSCI.5977-08.2009"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.\n                      Int J Obes\n                      . 2014;38:784\u201393.","DOI":"10.1038\/ijo.2013.162"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Peter R, Bain SC. Safety of injectable semaglutide for type 2 diabetes.\n                      Expert Opin Drug Saf\n                      . 2020;19:785\u201398.","DOI":"10.1080\/14740338.2020.1772230"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.\n                      N Engl J Med\n                      . 2017;377:1228\u201339.","DOI":"10.1056\/NEJMoa1612917"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.\n                      N Engl J Med\n                      . 2015;373:2247\u201357.","DOI":"10.1056\/NEJMoa1509225"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes.\n                      N Engl J Med\n                      . 2016;375:311\u201322.","DOI":"10.1056\/NEJMoa1603827"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial.\n                      Lancet\n                      . 2019;394:121\u201330.","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.\n                      N Engl J Med\n                      . 2016;375:1834\u201344.","DOI":"10.1056\/NEJMoa1607141"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.\n                      N Engl J Med\n                      . 2019;381:841\u201351.","DOI":"10.1056\/NEJMoa1901118"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial.\n                      Lancet\n                      . 2021;398:143\u201355.","DOI":"10.1016\/S0140-6736(21)01324-6"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.\n                      N Engl J Med\n                      . 2021;385:503\u201315.","DOI":"10.1056\/NEJMoa2107519"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Madsbad S. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.\n                      Diabetes Obes Metab\n                      . 2014;16:9\u201321.","DOI":"10.1111\/dom.12119"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management.\n                      N Engl J Med\n                      . 2015;373:11\u201322.","DOI":"10.1056\/NEJMoa1411892"},{"key":"ref41","unstructured":"European Medicines Agency. Saxenda recommended for approval in weight management in adults. 2015. Available at: www.ema.europa.eu\/en\/news\/saxenda-recommended-approval-weight-management-adults (accessed 14 March 2022)."},{"key":"ref42","unstructured":"US Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older. 2020. Available at: www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older (accessed 14 March 2022)."},{"key":"ref43","unstructured":"National Institute for Health and Care Excellence. NICE recommends new treatment option for adults with obesity and non-diabetic hyperglycaemia who have a high risk of cardiovascular disease. 2020. Available at: www.nice.org.uk\/news\/article\/nice-recommends-new-treatment-option-for-adults-with-obesity-and-non-diabetic-hyperglycaemia-who-have-a-high-risk-of-cardiovascular-disease (accessed 14 March 2022)."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5.\n                      Obesity (Silver Spring)\n                      . 2020;28:1050\u201361.","DOI":"10.1002\/oby.22794"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity.\n                      N Engl J Med\n                      . 2021;384:989.","DOI":"10.1056\/NEJMoa2032183"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.\n                      Lancet\n                      . 2021;397:971\u201384.","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial.\n                      JAMA\n                      . 2021;325:1403\u201313.","DOI":"10.1001\/jama.2021.1831"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial.\n                      JAMA\n                      . 2021;325:1414\u201325.","DOI":"10.1001\/jama.2021.3224"},{"key":"ref49","unstructured":"ClinicalTrials.gov. Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity (STEP 5). ClinicalTrials.gov Identifier: NCT03693430. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03693430 (accessed 2 August 2021)."},{"key":"ref50","unstructured":"ClinicalTrials.gov. Effect and Safety of Semaglutide Once-weekly in East Asian Subjects With Overweight or Obesity (STEP 6). ClinicalTrials.gov Identifier: NCT03811574. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT03811574 (accessed 2 August 2021)."},{"key":"ref51","unstructured":"ClinicalTrials.gov. Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity (STEP-7). ClinicalTrials.gov Identifier: NCT04251156. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04251156 (accessed 2 August 2021)."},{"key":"ref52","unstructured":"ClinicalTrials.gov. Effect and Safety of Subcutaneous Semaglutide 2.4 mg Once Weekly Compared to Liraglutide 3.0 mg Once Daily on Weight Management in Subjects With Overweight or Obesity (STEP-8). ClinicalTrials.gov Identifier: NCT04074161. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04074161 (accessed 2 August 2021)."},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design.\n                      Am Heart J\n                      . 2020;229:61\u20139.","DOI":"10.1016\/j.ahj.2020.07.008"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery.\n                      J Intern Med\n                      . 2013;273:219\u201334.","DOI":"10.1111\/joim.12012"},{"key":"ref55","unstructured":"ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1). ClinicalTrials.gov Identifier: NCT04184622. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT04184622 (accessed 20 November 2021)."},{"key":"ref56","unstructured":"ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight (SURMOUNT-2). ClinicalTrials.gov Identifier: NCT04657003. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT04657003 (accessed 20 November 2021)."},{"key":"ref57","unstructured":"National Institute for Health and Care Excellence. Semaglutide for Managing Overweight and Obesity [ID3850]. Available at: nice.org.uk\/guidance\/indevelopment\/gid-ta10765 (accessed 8 April 2021)."},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Johansen P, Chubb B, Hunt B, et al. Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-daily liraglutide for the treatment of type 2 diabetes in the UK.\n                      Adv Ther\n                      . 2020;37:2427\u201341.","DOI":"10.1007\/s12325-020-01337-7"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lee M, Lauren BN, Zhan T, et al. The cost-effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity.\n                      Obes Sci Pract\n                      . 2019;6:162\u201370.","DOI":"10.1002\/osp4.390"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/glucagon-like-peptide-1-receptor-analogues-for-the-treatment-of-obesity\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:59:38Z","timestamp":1764745178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.touchendocrinology.com\/diabetes\/journal-articles\/glucagon-like-peptide-1-receptor-analogues-for-the-treatment-of-obesity\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["EE.2022.18.1.43"],"URL":"https:\/\/doi.org\/10.17925\/ee.2022.18.1.43","relation":{},"ISSN":["2752-5457"],"issn-type":[{"value":"2752-5457","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}